Journal Home Online First Current Issue Archive For Authors Journal Information 中文版

Engineering >> 2021, Volume 7, Issue 10 doi: 10.1016/j.eng.2020.07.014

Mass Spectrometry Analysis of Newly Emerging Coronavirus HCoV-19 Spike Protein and Human ACE2 Reveals Camouflaging Glycans and Unique Post-Translational Modifications

a State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Disease, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310011, China
b Department of Biophysics & Center of Cryo-Electron Microscopy, Zhejiang University School of Medicine, Hangzhou 310011, China

Received: 2020-05-12 Revised: 2020-06-22 Accepted: 2020-07-05 Available online: 2020-08-30

Next Previous

Abstract

The coronavirus disease 2019 (COVID-19) pandemic has led to worldwide efforts to understand the biological traits of the newly identified human coronavirus (HCoV-19) virus. In this mass spectrometry (MS)-based study, we reveal that out of 21 possible glycosites in the HCoV-19 spike protein (S protein), 20 are completely occupied by N-glycans, predominantly of the oligomannose type. All seven glycosylation sites in human angiotensin I converting enzyme 2 (hACE2) were found to be completely occupied, mainly by complex N-glycans. However, glycosylation did not directly contribute to the binding affinity between HCoV-19 S protein and hACE2. Additional post-translational modification (PTM) was identified, including multiple methylated sites in both proteins and multiple sites with hydroxylproline in hACE2. Refined structural models of HCoV-19 S protein and hACE2 were built by adding N-glycan and PTMs to recently published cryogenic electron microscopy structures. The PTM and glycan maps of HCoV-19 S protein and hACE2 provide additional structural details for studying the mechanisms underlying host attachment and the immune response of HCoV-19, as well as knowledge for developing desperately needed remedies and vaccines.

SupplementaryMaterials

Figures

Fig. 1

Fig. 2

Fig. 3

Fig. 4

References

[ 1 ] Wu F, Zhao S, Yu B, Chen YM, Wang W, Song ZG, et al. A new coronavirus associated with human respiratory disease in China. Nature 2020;579:265–9. link1

[ 2 ] Dong E, Du H, Gardner L. An interactive web-based dashboard to track COVID19 in real time. Lancet Infect Dis 2020;20(5):533–4. link1

[ 3 ] Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 2020;579:270–3. link1

[ 4 ] Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020;382:1708–20. link1

[ 5 ] Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020;395(10229):1054–62. link1

[ 6 ] Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA 2020;323(11):1061–9. link1

[ 7 ] Zhang T, Wu Q, Zhang Z. Probable pangolin origin of SARS-CoV-2 associated with the COVID-19 outbreak. Curr Biol 2020;30(7):1346–51. link1

[ 8 ] Wu A, Peng Y, Huang B, Ding X, Wang X, Niu P, et al. Genome composition and divergence of the novel coronavirus (2019-nCoV). Cell Host Microbe 2020;27:325–8. link1

[ 9 ] Xu Y. Unveiling the origin and transmission of 2019-nCoV. Trends Microbiol 2020;28(4):239–40. link1

[10] Zhang YZ, Holmes EC. A genomic perspective on the origin and emergence of SARS-CoV-2. Cell 2020;181(2):223–7. link1

[11] Wan Y, Shang J, Graham R, Baric RS, Li F. Receptor recognition by the novel coronavirus: an analysis based on decade-long structural studies of SARS coronavirus. J Virol 2020;94(7):e00127–220. link1

[12] Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 2020;181(2):271–80.e8. link1

[13] Walls AC, Park YJ, Tortorici MA, Wall A, McGuire AT, Veesler D. Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell 2020;181 (2):281–92.e6. link1

[14] Wrapp D, Wang N, Corbett KS, Goldsmith JA, Hsieh CL, Abiona O, et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science 2020;367(6483):1260–3. link1

[15] Fukushi M, Yoshinaka Y, Matsuoka Y, Hatakeyama S, Ishizaka Y, Kirikae T, et al. Monitoring of S protein maturation in the endoplasmic reticulum by calnexin is important for the infectivity of severe acute respiratory syndrome coronavirus. J Virol 2012;86(21):11745–53. link1

[16] de Groot RJ. Structure, function and evolution of the hemagglutinin-esterase proteins of corona- and toroviruses. Glycoconj J 2006;23(1–2):59–72. link1

[17] Raman R, Tharakaraman K, Sasisekharan V, Sasisekharan R. Glycan-protein interactions in viral pathogenesis. Curr Opin Struct Biol 2016;40:153–62. link1

[18] Chang D, Zaia J. Why glycosylation matters in building a better flu vaccine. Mol Cell Proteomics 2019;18(12):2348–58. link1

[19] Li W, Hulswit RJG, Widjaja I, Raj VS, McBride R, Peng W, et al. Identification of sialic acid-binding function for the Middle East respiratory syndrome coronavirus spike glycoprotein. PNAS 2017;114(40):E8508–17. link1

[20] Parsons LM, Bouwman KM, Azurmendi H, de Vries RP, Cipollo JF, Verheije MH. Glycosylation of the viral attachment protein of avian coronavirus is essential for host cell and receptor binding. J Biol Chem 2019;294:7797–809. link1

[21] Shih YP, Chen CY, Liu SJ, Chen KH, Lee YM, Chao YC, et al. Identifying epitopes responsible for neutralizing antibody and DC-SIGN binding on the spike glycoprotein of the severe acute respiratory syndrome coronavirus. J Virol 2006;80(21):10315–24. link1

[22] York IA, Stevens J, Alymova IV. Influenza virus N-linked glycosylation and innate immunity. Biosci Rep 2018;39(1):BSR20171505. link1

[23] Zheng J, Yamada Y, Fung TS, Huang M, Chia R, Liu DX. Identification of N-linked glycosylation sites in the spike protein and their functional impact on the replication and infectivity of coronavirus infectious bronchitis virus in cell culture. Virology 2018;513:65–74. link1

[24] Zhou Y, Lu K, Pfefferle S, Bertram S, Glowacka I, Drosten C, et al. A single asparagine-linked glycosylation site of the severe acute respiratory syndrome coronavirus spike glycoprotein facilitates inhibition by mannose-binding lectin through multiple mechanisms. J Virol 2010;84(17):8753–64. link1

[25] Han DP, Lohani M, Cho MW. Specific asparagine-linked glycosylation sites are critical for DC-SIGN- and L-SIGN-mediated severe acute respiratory syndrome coronavirus entry. J Virol 2007;81(21):12029–39. link1

[26] Jeffers SA, Tusell SM, Gillim-Ross L, Hemmila EM, Achenbach JE, Babcock GJ, et al. CD209L (L-SIGN) is a receptor for severe acute respiratory syndrome coronavirus. PNAS 2004;101(44):15748–53. link1

[27] Zheng L, Li H, Fu L, Liu S, Yan Q, Leng SX. Blocking cellular N-glycosylation suppresses human cytomegalovirus entry in human fibroblasts. Microb Pathog 2020;138:103776. link1

[28] Vincent MJ, Bergeron E, Benjannet S, Erickson BR, Rollin PE, Ksiazek TG, et al. Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. Virol J 2005;2:69. link1

[29] Chen WH, Du L, Chag SM, Ma C, Tricoche N, Tao X, et al. Yeast-expressed recombinant protein of the receptor-binding domain in SARS-CoV spike protein with deglycosylated forms as a SARS vaccine candidate. Hum Vaccines Immunother 2014;10(3):648–58. link1

[30] Kumar S, Maurya VK, Prasad AK, Bhatt MLB, Saxena SK. Structural, glycosylation and antigenic variation between 2019 novel coronavirus (2019-nCoV) and SARS coronavirus (SARS-CoV). VirusDisease 2020;31:13–21. link1

[31] Sun Z, Liu X, Jiang J, Huang H, Wang J, Wu D, et al. Toward biomarker development in large clinical cohorts: an integrated high-throughput 96-wellplate-based sample preparation workflow for versatile downstream proteomic analyses. Anal Chem 2016;88(17):8518–25. link1

[32] Liu MQ, Zeng WF, Fang P, Cao WQ, Liu C, Yan GQ, et al. pGlyco 2.0 enables precision N-glycoproteomics with comprehensive quality control and one-step mass spectrometry for intact glycopeptide identification. Nat Commun 2017;8:438. link1

[33] Emsley P, Lohkamp B, Scott WG, Cowtan K. Features and development of Coot. Acta Crystallogr 2010;D66:486–501. link1

[34] Bailey UM, Jamaluddin MF, Schulz BL. Analysis of congenital disorder of glycosylation-Id in a yeast model system shows diverse site-specific underglycosylation of glycoproteins. J Proteome Res 2012;11:5376–83. link1

[35] Shajahan A, Supekar NT, Gleinich AS, Azadi P. Deducing the N- and Oglycosylation profile of the spike protein of novel coronavirus SARS-CoV-2. Glycobiology 2020;30(12):981–8.

[36] Watanabe Y, Allen JD, Wrapp D, McLellan JS, Crispin M. Site-specific glycan analysis of the SARS-CoV-2 spike. Science 2020;369(6501):330–3. link1

[37] Krokhin O, Li Y, Andonov A, Feldmann H, Flick R, Jones S, et al. Mass spectrometric characterization of proteins from the SARS virus: a preliminary report. Mol Cell Proteomics 2003;2(5):346–56. link1

[38] Ying W, Hao Y, Zhang Y, Peng W, Qin E, Cai Y, et al. Proteomic analysis on structural proteins of severe acute respiratory syndrome coronavirus. Proteomics 2004;4(2):492–504. link1

[39] Song HC, Seo MY, Stadler K, Yoo BJ, Choo QL, Coates SR, et al. Synthesis and characterization of a native, oligomeric form of recombinant severe acute respiratory syndrome coronavirus spike glycoprotein. J Virol 2004;78 (19):10328–35. link1

[40] Watanabe Y, Bowden TA, Wilson IA, Crispin M. Exploitation of glycosylation in enveloped virus pathobiology. Biochim Biophys Acta Gen Subj 2019;1863 (10):1480–97. link1

[41] Feldmann H, Nichol ST, Klenk HD, Peters CJ, Sanchez A. Characterization of filoviruses based on differences in structure and antigenicity of the virion glycoprotein. Virology 1994;199(2):469–73. link1

[42] Ritchie G, Harvey DJ, Feldmann F, Stroeher U, Feldmann H, Royle L, et al. Identification of N-linked carbohydrates from severe acute respiratory syndrome (SARS) spike glycoprotein. Virology 2010;399(2):257–69. link1

[43] Yang TJ, Chang YC, Ko TP, Draczkowski P, Chien YC, Chang YC, et al. Cryo-EM analysis of a feline coronavirus spike protein reveals a unique structure and camouflaging glycans. PNAS 2020;117(3):1438–46. link1

[44] Vigerust DJ, Shepherd VL. Virus glycosylation: role in virulence and immune interactions. Trends Microbiol 2007;15(5):211–8. link1

[45] Biswas A, Bhattacharjee U, Chakrabarti AK, Tewari DN, Banu H, Dutta S. Emergence of novel coronavirus and COVID-19: whether to stay or die out? Crit Rev Microbiol 2020;46(2):182–93. link1

[46] Robinson BS, Arthur CM, Evavold B, Roback E, Kamili NA, Stowell CS, et al. The sweet-side of leukocytes: galectins as master regulators of neutrophil function. Front Immunol 2019;53(6):925–35. link1

[47] Wang WH, Lin CY, Chang MR, Urbina AN, Assavalapsakul W, Thitithanyanont A, et al. The role of galectins in virus infection—a systemic literature review. J Microbiol Immunol Infect 2019;53(6):925–35. link1

[48] Cheng Y, Cheng G, Chui CH, Lau FY, Chan PK, Ng MH, et al. ABO blood group and susceptibility to severe acute respiratory syndrome. JAMA 2005;293 (12):1450–1. link1

[49] Zhao J, Yang Y, Huang H, Li D, Gu D, Lu X, et al. Relationship between the ABO blood group and the COVID-19 susceptibility. Clin Infect Dis 2020;73(2):328– 31.

[50] Guillon P, Clément M, Sébille V, Rivain JG, Chou CF, Ruvoën-Clouet N, et al. Inhibition of the interaction between the SARS-CoV spike protein and its cellular receptor by anti-histo-blood group antibodies. Glycobiology 2008;18 (12):1085–93. link1

[51] Zhao X, Guo F, Comunale MA, Mehta A, Sehgal M, Jain P, et al. Inhibition of endoplasmic reticulum-resident glucosidases impairs severe acute respiratory syndrome coronavirus and human coronavirus NL63 spike protein-mediated entry by altering the glycan processing of angiotensin I-converting enzyme 2. Antimicrob Agents Chemother 2015;59(1):206–16. link1

[52] Liu J, Cao R, Xu M, Wang X, Zhang H, Hu H, et al. Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. Cell Discovery 2020;6:16. link1

Related Research